Emerging antidementia drugs: a preliminary ethical view.
What ethical concerns regarding the application of new antidementia compounds are pertinent to the best interests of patients with Alzheimer's disease and their caregivers? Based on collected preliminary anecdotal accounts, these concerns are important and should be considered carefully by clinicians, researchers, and families.
Post
S G
SG
Center for Biomedical Ethics, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Whitehouse
P J
PJ
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D026686:Beneficence; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003704:Dementia / Q000188:drug therapy*; D000077265:Donepezil; D004992:Ethics, Medical; D005260:Female; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D008297:Male; D018697:Nootropic Agents / Q000627:therapeutic use*; D010347:Patient Care Planning; D010880:Piperidines / Q000627:therapeutic use; D011368:Professional-Family Relations; D011788:Quality of Life; D018570:Risk Assessment; D028761:Withholding Treatment
D002800:Cholinesterase Inhibitors; D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil